The Non-glycemic Effects of SGLT2 Inhibitor

Abstract

Sodium glucose cotransporter 2 (SGLT2) inhibitors have recently been introduced as a new class of antidiabetic agents. In addition to their glycemic action, SGLT2 inhibitors also have a number of non-glycemic effects that may contribute to renal and/or cardiovascular benefits. These include effects on tubuloglomerular feedback in the kidney, body weight, blood pressure, and serum uric acid. Other non-glycemic effects of SGLT2 inhibitors that need to be further studied include the effects on lipid profiles, food intake, and secretion of hormones such as leptin, incretins, and aldosterone. Also, the exact mechanisms of various non-glycemic actions should be further studied. Additionally, SGLT2 inhibitor therapy in combination with other drugs may have beneficial glycemic and non-glycemic effects. (

Need of the hour: pharmacovigilance study of SGLT-2 inhibitors

“…Three drugs, namely dapagliflozin, empagliflozin and canagliflozin have been recently introduced in India. 15,16 SGLT-2 inhibitors although considered to be well tolerated, potential adverse effects of urinary tract infections and mycotic genital tract infections exists due to continuous presence of urinary glucose. 17 By increasing renal tubular reabsorption of phosphate and parathyroid hormone secretion SGLT-2 inhibitors increase FGF-23 secretion from osteocytes which causes bone resorption leading to fractures.…”